Jason Adair Sells 7,863 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 7,863 shares of the firm’s stock in a transaction on Monday, July 13th. The shares were sold at an average price of $71.51, for a total transaction of $562,283.13. Following the sale, the insider owned 217,126 shares in the company, valued at approximately $15,526,680.26. This trade represents a 3.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, April 27th, Jason Adair sold 688 shares of Liquidia stock. The stock was sold at an average price of $41.65, for a total transaction of $28,655.20.

Liquidia Stock Up 1.6%

LQDA opened at $77.75 on Thursday. The stock has a market cap of $6.91 billion, a PE ratio of 555.40 and a beta of 0.55. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 52 week low of $14.04 and a 52 week high of $82.96. The business’s fifty day simple moving average is $67.08 and its 200 day simple moving average is $47.81.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The business’s revenue was up 4187.1% compared to the same quarter last year. As a group, research analysts expect that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Wall Street Zen cut shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. HC Wainwright lifted their price target on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, June 5th. Oppenheimer set a $75.00 price objective on shares of Liquidia in a report on Friday, June 5th. Finally, Wells Fargo & Company upped their price objective on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Three investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $68.88.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s YUTREPIA patent case appears to be turning more favorable, and the company is also being highlighted for expanding its patent position around the drug. That improves the outlook for protecting its pulmonary hypertension franchise and supports the bullish case for the stock. Liquidia (LQDA) Expands YUTREPIA As Patent Case Turns More Favorable
• Neutral Sentiment: Brokerage coverage remains constructive overall, with Liquidia receiving a consensus “Moderate Buy” rating from analysts. That supports the stock’s longer-term outlook, but it is not a new catalyst on its own. Liquidia Corporation (NASDAQ:LQDA) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Negative Sentiment: Several insiders, including the CEO, CFO, general counsel, CAO, and others, disclosed stock sales at about the same price level. The trades were made under pre-arranged 10b5-1 plans and tied to tax withholding from equity vesting, but the size and number of sales may still raise some investor caution. SEC filing – Roger Jeffs sale

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. purchased a new stake in Liquidia during the 4th quarter valued at $25,000. NewEdge Advisors LLC bought a new stake in Liquidia in the 2nd quarter worth $25,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia in the third quarter valued at about $34,000. Covestor Ltd increased its position in shares of Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in shares of Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after acquiring an additional 4,927 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).